Meta-analysis · people
PT-141: side-effect dropouts far higher than placebo in re-analysis
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
This re-analysis of the main PT-141 trials in women with low sexual desire found modest benefits and much higher odds of quitting due to side effects than on placebo, and it concludes the drug is generally not useful.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2021
- Journal
- J Sex Res
What they tested
This re-analysis asked whether the published results of two Phase III bremelanotide trials for hypoactive sexual desire disorder (HSDD, persistently low sexual desire) in women gave a complete picture of benefit and harm.
How the study was done
A single-author meta-analysis that pooled data from two 24-week Phase III trials, drawn from the FDA New Drug Application. It also compared the original published report against the trials' protocols.

What they found
Benefits were similar to the original report's, but the author judged them modest and measured on post hoc outcomes of questionable validity. Women on bremelanotide had much higher odds of leaving the trial because of side effects (odds ratio 11.98, 95% CI 3.74-38.37, number needed to harm 6). They were also less likely to both finish the trial and choose to join the open-label follow-up study (odds ratio 0.30, number needed to harm 4), which the author read as a preference for placebo. The original paper left out 72.72% of the outcomes listed in the protocols and presented 15 secondary measures the protocols never listed.
What it doesn’t show
This is one author's re-analysis of two existing trials, not a new trial. Treating trial completion plus joining the follow-up study as a preference for placebo is an indirect measure.
The paper
Spielmans Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res. 2021.
The compound
More studies on PT-141
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.